Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.


Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?


Please Try Again {{ error }}

Send my password

An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Opinion & Analysis Resverlogix Corp. T.RVX

Alternate Symbol(s):  RVXCF | T.RVX.W.A

Resverlogix Corp clinical-stage biotechnology company. The company is developing an advanced epigenetic drug called apabetalone for the treatment of patients with cardiovascular disease, diabetes mellitus, chronic kidney disease, peripheral artery disease, orphan diseases, and neurodegenerative diseases.

Opinion & Analysis (TSX:RVX)

    Buzz on the Bullboards: Will Cooler Heads Prevail?

    Omri Wallach October 3, 2019

    'Pivotal Topline Up Next' for Biotech's Phase 3 Cardiac Clinical Trial

    Streetwise Reports May 2, 2019

    Biotech’s Lead Drug Candidate Targets 'Market with Huge Potential'

    Streetwise Reports November 2, 2018

    Biotech's shares 'undervalued' and positioned for 'long-term upside potential'

    Streetwise Reports December 28, 2017

    Biotech receives 'major endorsement from world-leading pharma company'

    Streetwise Reports December 21, 2017

    Coverage initiated on 'one of the most undervalued biotech companies in Canada'

    Streetwise Reports December 8, 2017

    With completion of offer, analyst says this biotech stock could triple

    The Life Sciences Report June 28, 2017

    Resverlogix seeks orphan status for lead drug candidate

    The Life Sciences Report August 4, 2016

    How three companies have been resurrected from failed clinical trials:George Zavoico of JonesTrading

    The Life Sciences Report April 6, 2016

    Circling the globe for uncommon biotech opportunities

    The Life Sciences Report February 18, 2016

    Disrupting treatment of cardiovascular disease with epigenetics: Resverlogix CEO Donald McCaffrey

    Gail Dutton August 26, 2015

    Probe biotech's diverse subsectors for strong, undervalued companies: Van Leeuwenhoeck's Marcel Wijma

    Gail Dutton July 2, 2015

    Blogger says 2014 may be a good year for Canadian Zinc (T.CZN)

    Stockhouse Editorial December 24, 2013

    Stockhouse Research: Sometimes no news is good news

    Chris Parry September 10, 2013

    Stockhouse Research: The day Niko Resources came to play

    Chris Parry September 6, 2013

    Stockhouse Research: Resverlogix (T.RVX) and Colabor (T.GCL) sparking interest

    Chris Parry September 3, 2013